Health Care [ 10/12 ] | Health Care Equipment & Supplies [ 67/73 ]
NASDAQ | Common Stock
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.
The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations.
It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases; and Modified HSV-1, which is in the discovery phase, for the treatment of modified colorectal cancer.
The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease.
It also has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders.
The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 25 | -0.21 Increased by +18.51% | - |
| Mar 14, 25 | -0.19 Increased by +10.71% | - |
| Sep 30, 24 | -0.22 Decreased by -5.54% | - |
| Jun 30, 24 | -0.20 Increased by +18.85% | - |
| Mar 31, 24 | -0.26 Decreased by -134.27% | - |
| Dec 31, 23 | -0.21 Decreased by -112.80% | - |
| Sep 30, 23 | -0.21 | - |
| Jun 30, 23 | -0.24 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -2.02 M Decreased by -5.98% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 1.72 K Increased by 0.00% | -1.71 M Decreased by -32.21% | Decreased by -99.46 K% Decreased by -32.21% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -1.76 M Decreased by -40.74% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.61 M Decreased by -8.87% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -1.90 M Decreased by -43.62% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.72 K Decreased by -82.76% | -1.30 M Decreased by -86.47% | Decreased by -75.23 K% Decreased by -981.62% |
| Sep 30, 23 | 65.00 K Increased by +N/A% | -1.25 M Decreased by -63.85% | Decreased by -1.93 K% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.48 M Decreased by -90.79% | Decreased by N/A% Decreased by N/A% |